alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
United States Court of Appeals 

for the Fifth Circuit ____________ 

No. 23-40368 

Summary Calendar 

____________ 

United States of America, 

Plaintiff—Appellee, 

versus

Eleuterio Covarrubias-Martinez, 

Defendant—Appellant. 

______________________________ 

Appeal from the United States District Court 

for the Southern District of Texas 

USDC No. 7:22-CR-1932-1 

______________________________ 

Before Smith, Higginson, and Engelhardt, Circuit Judges.

Per Curiam:*

Eleuterio Covarrubias-Martinez appeals his conviction and sentence 

for being found in the United States after a previous deportation. He argues 

that 8 U.S.C. § 1326(b) is unconstitutional because it allows a sentence above 

the otherwise applicable statutory maximum established by § 1326(a) based 

_____________________ 

*

 This opinion is not designated for publication. See 5th Cir. R. 47.5. 

United States Court of Appeals 

Fifth Circuit 

FILED 

November 17, 2023 

Lyle W. Cayce 

Clerk 

Case: 23-40368 Document: 00516973176 Page: 1 Date Filed: 11/17/2023
No. 23-40368 

2 

on facts that are neither alleged in the indictment nor found by a jury beyond 

a reasonable doubt. 

Covarrubias-Martinez has filed an unopposed motion for summary 

disposition and a letter brief correctly conceding that the only issue he raises 

is foreclosed by Almendarez-Torres v. United States, 523 U.S. 224 (1998). See 

United States v. Pervis, 937 F.3d 546, 553-54 (5th Cir. 2019). He explains that 

he has raised the issue to preserve it for possible further review. Accordingly, 

because summary disposition is appropriate, see Groendyke Transp., Inc. v. 

Davis, 406 F.2d 1158, 1162 (5th Cir. 1969), Covarrubias-Martinez’s motion 

is GRANTED, and the district court’s judgment is AFFIRMED. 

Case: 23-40368 Document: 00516973176 Page: 2 Date Filed: 11/17/2023
§ 520.1380 Methocarbamol. ( a ) *Specifications.* Each tablet contains 500 milligrams (mg) of methocarbamol.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Administer 60 mg per pound of body weight in two or three equally divided doses, followed each following day by 30 to 60 mg per pound of body weight, usually not to exceed 14 to 21 days.
( 2 ) *Indications for use.* As an adjunct to therapy for acute inflammatory and traumatic conditions of the skeletal muscles in order to reduce muscular spasms.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[78 FR 28824, May 20, 2014]
### Magnitude and frequency of floods in the United States; part 2-B. South Atlantic slope and Eastern Gulf of Mexico basins, Ogeechee River to Pearl River

By: Harry H. BarnesHarold G. Golden

                            https://doi.org/10.3133/wsp1674

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- NGMDB Index Page:  **National Geologic Map Database Index Page**                            (html)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
§ 310.517 Labeling for oral hypoglycemic drugs of the sulfonylurea class. ( a ) The University Group Diabetes Program clinical trial has reported an association between the administration of tolbutamide and increased cardiovascular mortality. The Food and Drug Administration has concluded that this reported association provides adequate basis for a warning in the labeling. In view of the similarities in chemical structure and mode of action, the Food and Drug Administration also believes it is prudent from a safety standpoint to consider that the possible increased risk of cardiovascular mortality from tolbutamide applies to all other sulfonylurea drugs as well. Therefore, the labeling for oral hypoglycemic drugs of the sulfonylurea class shall include a warning concerning the possible increased risk of cardiovascular mortality associated with such use, as set forth in paragraph (b) of this section.
( b ) Labeling for oral hypoglycemic drugs of the sulfonylurea class shall include in boldface type at the beginning of the “Warnings” section of the labeling the following statement:
Special Warning on Increased Risk of Cardiovascular Mortality The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes,* 19 (supp. 2): 747-830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 21 ⁄ 2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of (name of drug) and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.
[49 FR 14331, Apr. 11, 1984]
§ 520.1629 Oxfendazole paste. ( a ) ( 1 ) *Specifications.* Each gram of paste contains 0.375 gram oxfendazole (37.5 percent).
( 2 ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( 3 ) *Conditions of use* — ( i ) *Amount.* 10 milligrams per kilogram (2.2 pounds) of body weight.
( ii ) *Indications for use.* The drug is used in horses for removal of the following gastrointestinal worms: Large roundworms (*Parascaris equorum*), mature and 4th stage larvae pinworms (*Oxyuris equi*), large strongyles (*Strongylus edentatus, S. vulgaris,* and *S. equinus*), and small strongyles.
( iii ) *Limitations.* Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks. Withholding feed or water prior to use is unnecessary. Administer drug with caution to sick or debilitated horses. Not for use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
( b ) ( 1 ) *Specifications.* Each gram of paste contains 185 milligrams of oxfendazole (18.5 percent).
( 2 ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( 3 ) *Related tolerances.* See § 556.495 of this chapter.
( 4 ) *Conditions of use* — ( i ) *Amount.* 4.5 milligrams per kilogram of body weight (2.05 milligrams per pound).
( ii ) *Indications for use.* The drug is used in cattle for the removal and control of the following worms: lungworms (*Dictyocaulus viviparus*—adult, L4); stomach worms: barberpole worms (*Haemonchus contortus* and *H. placei*—adult), small stomach worms (*Trichostrongylus axei*—adult), brown stomach worms (*Ostertagia ostertagi*—adult, L4, inhibited L4); intestinal worms; nodular worms (*Oesophagostomum radiatum*—adult), hookworms (*Bunostomum phlebotomum*—adult), small intestinal worms (*Cooperia punctata, C. oncophora,* and *C. mcmasteri*—adult, L4); and tapeworms (*Moniezia benedeni*—adult).
( iii ) *Limitations.* For use in cattle only. Treatment may be repeated in 4 to 6 weeks. Cattle must not be slaughtered until 11 days after treatment. Do not use in female dairy cattle of breeding age. Consult a veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
[49 FR 38250, Sept. 28, 1984, as amended at 58 FR 39443, July 23, 1993; 61 FR 5506, Feb. 13, 1996; 78 FR 28825, May 20, 2014]
**Exhibit
32(b)**
 
 **Certification
of Chief Financial Officer Pursuant to 18 U.S.C. § 1350**
 **(Section
906 of the Sarbanes-Oxley Act of 2002)**
 
 Pursuant
to 18 U.S.C. § 1350, the undersigned officer of Republic Bancorp Inc. (the
“Company”) hereby certifies, to such officer’s knowledge, that the Company’s
Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2005
(the “Report”) fully complies with the requirements of Section 13(a) or 15(d),
as applicable, of the Securities Exchange Act of 1934 and that the information
contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.
 
 
 Date:
      November 8, 2005
    /s/
      Thomas F. MenacherName:
      Thomas F. MenacherTitle:
      Executive Vice President, Treasurer and Chief Financial
      Officer
 
 The
foregoing certification (i) accompanies the filing and is being furnished solely
pursuant to 18 U.S.C. § 1350, (ii) will not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the
liability of that section, and (iii) will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933 or the Exchange Act,
except to the extent that the registrant specifically incorporates it by
reference.
 
 
 A signed
original of this written statement required by Section 906, or other document
authenticating, acknowledging, or otherwise adopting the signature that appears
in typed form within the electronic version of this written statement required
by Section 906, has been provided to Republic Bancorp Inc. and will be retained
by Republic Bancorp Inc. and furnished to the Securities and Exchange Commission
or its staff upon request.
# L_2019026EN.01000901.xml

| 30.1.2019 | EN | Official Journal of the European Union | L 26/9 |
| --- | --- | --- | --- |

30.1.2019

EN

Official Journal of the European Union

L 26/9

---

COUNCIL DECISION (EU) 2019/141

of 28 January 2019

appointing an alternate member, proposed by the Federal Republic of Germany, of the Committee of the Regions

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 305 thereof,

Having regard to the proposal of the German Government,

Whereas:

| (1) | On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020. |
| --- | --- |

(1)

On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020.

| (2) | An alternate member's seat on the Committee of the Regions has become vacant following the passing away of Mr Ralf GEISTHARDT, |
| --- | --- |

(2)

An alternate member's seat on the Committee of the Regions has become vacant following the passing away of Mr Ralf GEISTHARDT,

HAS ADOPTED THIS DECISION:

Article 1

The following is hereby appointed as an alternate member of the Committee of the Regions for the remainder of the current term of office, which runs until 25 January 2020:

Mr Markus KURZE, Mitglied des Landtages von Sachsen-Anhalt.

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 28 January 2019.

For the Council

The President

P. DAEA

---

(1)  Council Decision (EU) 2015/116 of 26 January 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 20, 27.1.2015, p. 42).

1

(2)  Council Decision (EU) 2015/190 of 5 February 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 31, 7.2.2015, p. 25).

2

(3)  Council Decision (EU) 2015/994 of 23 June 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 159, 25.6.2015, p. 70).

3

---
Exhibit 32.1
 CERTIFICATION PURSUANT TO  18 U.S.C. SECTION 1350  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  (1)
    
    The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and(2)
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
 /s/ WILLIAM C. GRIFFITHSWilliam C. GriffithsChairman of the Board of Directors,President and Chief Executive OfficerChampion Enterprises, Inc.April 30, 2009/s/ PHYLLIS A. KNIGHTPhyllis A. KnightExecutive Vice President, Treasurer andChief Financial OfficerChampion Enterprises, Inc.April 30, 2009
STATE DOMESTIC PREPAREDNESS PROGRAM

 FISCAL YEAR 2002 FUNDING ALLOCATIONS

STATE NAME

EQUIPMENT

ALLOCATION

EXERCISE

ALLOCATION

TOTAL

ALLOCATION

ALABAMA 5,081,000 236,000 5,317,000

ALASKA 2,660,000 123,000 2,783,000

ARIZONA 5,514,000 256,000 5,770,000

ARKANSAS 3,957,000 184,000 4,141,000

CALIFORNIA 23,730,000 1,101,000 24,831,000

COLORADO 4,989,000 231,000 5,220,000

CONNECTICUT 4,421,000 205,000 4,626,000

DELAWARE 2,759,000 128,000 2,887,000

DISTRICT OF COLUMBIA 2,625,000 122,000 2,747,000

FLORIDA 12,392,000 575,000 12,967,000

GEORGIA 7,451,000 346,000 7,797,000

HAWAII 3,031,000 141,000 3,172,000

IDAHO 3,083,000 143,000 3,226,000

ILLINOIS 10,134,000 470,000 10,604,000

INDIANA 6,116,000 284,000 6,400,000

IOWA 4,117,000 191,000 4,308,000

KANSAS 3,967,000 184,000 4,151,000

KENTUCKY 4,824,000 224,000 5,048,000

LOUISIANA 5,095,000 236,000 5,331,000

MAINE 3,071,000 142,000 3,213,000

MARYLAND 5,620,000 261,000 5,881,000

MASSACHUSETTS 6,287,000 292,000 6,579,000

MICHIGAN 8,561,000 397,000 8,958,000

MINNESOTA 5,381,000 250,000 5,631,000

MISSISSIPPI 4,066,000 189,000 4,255,000

MISSOURI 5,809,000 270,000 6,079,000

MONTANA 2,835,000 132,000 2,967,000

NEBRASKA 3,347,000 155,000 3,502,000

NEVADA 3,529,000 164,000 3,693,000

NEW HAMPSHIRE 3,046,000 141,000 3,187,000

NEW JERSEY 7,596,000 352,000 7,948,000

NEW MEXICO 3,416,000 158,000 3,574,000

NEW YORK 14,290,000 663,000 14,953,000

NORTH CAROLINA 7,364,000 342,000 7,706,000

NORTH DAKOTA 2,670,000 124,000 2,794,000

OHIO 9,458,000 439,000 9,897,000

OKLAHOMA 4,450,000 206,000 4,656,000

OREGON 4,431,000 206,000 4,637,000

PENNSYLVANIA 10,046,000 466,000 10,512,000

RHODE ISLAND 2,927,000 136,000 3,063,000

SOUTH CAROLINA 4,805,000 223,000 5,028,000

SOUTH DAKOTA 2,741,000 127,000 2,868,000

TENNESSEE 5,868,000 272,000 6,140,000

TEXAS 15,478,000 718,000 16,196,000

UTAH 3,678,000 171,000 3,849,000

VERMONT 2,649,000 123,000 2,772,000

VIRGINIA 6,749,000 313,000 7,062,000

WASHINGTON 5,998,000 278,000 6,276,000

WEST VIRGINIA 3,409,000 158,000 3,567,000

WISCONSIN 5,662,000 263,000 5,925,000

WYOMING 2,576,000 120,000 2,696,000

PUERTO RICO 4,677,000 217,000 4,894,000

VIRGIN ISLANDS 823,000 38,000 861,000

AMERICAN SAMOA 791,000 37,000 828,000

GUAM 852,000 40,000 892,000

NORTHERN MARIANA ISLANDS 798,000 37,000 835,000

TOTAL 301,700,000 14,000,000 315,700,000
I 

118TH CONGRESS 

2D SESSION H. R. 7478 

To amend the Higher Education Act of 1965 to require institutions of 

higher education, as a condition of participation in programs under 

title IV of such Act, to include a prohibition of antisemitic conduct 

in all documents relating to student or employee conduct. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 29, 2024 

Mr. YAKYM introduced the following bill; which was referred to the Committee 

on Education and the Workforce 

A BILL 

To amend the Higher Education Act of 1965 to require 

institutions of higher education, as a condition of participation in programs under title IV of such Act, to include 

a prohibition of antisemitic conduct in all documents 

relating to student or employee conduct. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Promote Restoring 

5 Order To End Campus Targeting of Jewish Students and 

6 Faculty Act’’ or the ‘‘PROTECT Jewish Student and 

7 Faculty Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7478 IH

1 SEC. 2. PROHIBITION OF ANTISEMITIC CONDUCT. 

2 Section 487(a) of the Higher Education Act of 1965 

3 (20 U.S.C. 1094(a)) is amended by adding at the end the 

4 following: 

5 ‘‘(30) The institution will include, in all docu6 ments and other resources relating to student or em7 ployee conduct on campus— 

8 ‘‘(A) the working definition of antisemitism 

9 of the International Holocaust Remembrance 

10 Alliance; and 

11 ‘‘(B) a statement that antisemitic conduct 

12 is prohibited on campus, and that such con13 duct— 

14 ‘‘(i) by a student may result in the ex15 pulsion of the student from the institution; 

16 and 

17 ‘‘(ii) by an employee may result in the 

18 termination of the employee’s employment 

19 at the institution.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
Editorial Note on Part 14
Editorial Note: Nomenclature changes to part 14 appear at 88 FR 45065, July 14, 2023.

§ 14.39 Additional rules for a particular advisory committee. ( a ) In addition to these rules, an advisory committee may, with the concurrence of the designated Federal employee, adopt additional rules which are not inconsistent with this subpart or with other legal requirements.
( b ) Any additional rules will be included in the minutes of the meeting when adopted and in the materials compiled under § 14.33 and will be available for public disclosure under § 14.65(c).
# L_2020230EN.01003601.xml

| 17.7.2020 | EN | Official Journal of the European Union | L 230/36 |
| --- | --- | --- | --- |

17.7.2020

EN

Official Journal of the European Union

L 230/36

---

Corrigendum to Council Decision (CFSP) 2019/797 of 17 May 2019 concerning restrictive measures against cyber-attacks threatening the Union or its Member States

(
  Official Journal of the European Union L 129 I of 17 May 2019
  )

On page 16, Article 5(3), first subparagraph, point (a):

for:

| ‘(a) | necessary to satisfy the basic needs of the natural persons listed in the Annex ...’, |
| --- | --- |

‘(a)

necessary to satisfy the basic needs of the natural persons listed in the Annex ...’,

read:

| ‘(a) | necessary to satisfy the basic needs of the natural or legal persons, entities or bodies listed in the Annex ...’. |
| --- | --- |

‘(a)

necessary to satisfy the basic needs of the natural or legal persons, entities or bodies listed in the Annex ...’.

---
[No. 38496-1-I.

Division One.

October 27, 1997.]

#### The State of Washington, *Respondent,*v. John D. Babcock, *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 92-1-00352-6, JoAnne Alumbaugh, J., entered January 31, 1997. *Affirmed*by unpublished per curiam opinion.
[No. 16246-0-III.

Division Three.

December 11, 1997.]

#### The State of Washington, *Respondent,*v. Allen L. Slater, *Appellant.*

Appeal from a judgment of the Superior Court for Kittitas County, No. 96-1-00132-4, Michael E. Cooper, J., entered November 14, 1996. *Affirmed*by unpublished opinion per Kurtz, J., concurred in by Sweeney, C.J., and Kato, J.
---

---

Exhibit
  13.2


Section 906
  CertificationCERTIFICATION OF
  CHIEF FINANCIAL OFFICERPURSUANT TO 18 U.S.C.
  SECTION 1350

In
  connection with the accompanying Annual Report on Form 20-F of NUR Macroprinters
  Ltd. for the year ended December 31, 2003, the undersigned officer, being the
  Chief Financial Officer of NUR Macroprinters Ltd., hereby certifies pursuant
  to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
  Act of 2002, that:

| | (1) | such Annual Report on Form 20-F for the year ended December 31, 2003 fully
      complies with the requirements of Section 13(a) or 15(d) of the Securities
      Exchange Act of 1934; and                                                
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |     |                                                                                                                                                                                                                                            
| | (2) | the
      information contained in such Annual Report on Form 20-F for the year ended
      December 31, 2003 fairly presents, in all material respects, the financial
      condition and results of operations of NUR Macroprinters Ltd..

This written statement
    is being furnished to the Securities and Exchange Commission as an exhibit
    to such Form 20-F.

|March
      30, 2004 |                                                    
|-------------------- | ---------------------------------------------------
|                     |                                                    
|Date                 |                                                    
|                     |                                                    
|                     | /s/ David
      Seligman                           
|                     |                                                    
|                     | David
      Seligman 
      Chief Financial Officer

---

---
<PAGE>   1

                                                                    EXHIBIT 23.4




                        Independent Accountants' Consent


The Board of Directors
HUB Financial Corporation:

We consent to the use of our report included herein and to the reference to our
firm under the heading "Experts" in the prospectus.


/s/ KPMG PEAT MARWICK, LLP

   
Billings, Montana
July 10, 1998